Skip to content

CAMBRIDGE, Mass., Jan. 6, 2015— Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that Stéphane Bancel, president and chief executive officer of Moderna, will present a company overview at the 33rd Annual J.P. Morgan Healthcare Conference.

Bancel will focus on Moderna’s efforts to accelerate drug discovery and development across a series of drug modalities and therapeutic areas, each powered by Moderna’s proprietary approach for utilizing modified mRNA to instruct native cellular machinery to make therapeutic proteins in vivo.

The presentation will take place on Tuesday, January 13, 2015 at 8:30 a.m. PT in Elizabethan D at the Westin St. Francis Hotel in San Francisco.

For more information on Moderna Therapeutics, including how messenger RNA works, partnership opportunities, and open job opportunities, visit

About Moderna Therapeutics

Moderna is pioneering messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. The company currently plans to develop and commercialize its innovative mRNA drugs through a combination of strategic relationships as well as newly formed ventures, including Onkaido LLC, focused on oncology drug development. Founded by Flagship VentureLabs™, Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca and Alexion Pharmaceuticals.